Optimizing cardiovascular gene therapy: Increased vascular gene transfer with modified adenoviral vectors

Archives of Surgery

Volumn 135, Issue 2, 2000, Pages 191-197

  Kibbe, Melina R ^a   Murdock, Alan ^a   Wickham, Thomas ^b   Lizonova, Alena ^b   Kovesdi, Imre ^b   Nic, Suhua ^a   Shears, Larry ^a   Billiar, Timothy R ^a   Tzeng, Edith ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b GENVEC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; HEPARAN SULFATE; HEPARIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ARTICLE; GENE TARGETING; GENE THERAPY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0033980042     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.135.2.191     Document Type: Article

References (16)

1. Kibbe MR, Billiar TR, Tzeng E. Gene therapy and vascular disease. Adv Pharmacol. 1999;46:85-150.
2. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol. 1997;40:137-206.
3. Roelvink PW, Lizonova A, Lee JG, et al. The Coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol. 1998;72:7909-7915.
4. Bergelson JM, Krithivas A, Cell L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998;72:415-419.
5. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J. 1997;16:2294-2306.
6. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric liber proteins. J Virol. 1997;71: 8221-8229.
7. Shears LL, Kibbe MR, Murdock AD, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg. 1998;187:295-306.
8. Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996;70:6497-6501.
9. Kim S, Lin H, Barr E, Chu L, Leiden JM, Parmacek MS. Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. J Clin Invest. 1997;100:1006-1014.
10. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol. 1996;14:1570-1573.
11. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 1995;2:750-756.
12. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 1996; 70:6839-6846.
13. Stevenson SC, Rollence M, White B Weaver L, McClelland A. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol. 1995;69:2850-2857.
14. Rosengart TK, Patel SR, Lee LY, et al. Safety of direct myocardial VEGF121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery [abstract]. Circulation. 1998;98(suppl 17):l-319.
15. Laitinen M, Hartikainen J, Eranen J, et al. Catheter-mediated VEGF gene transfer to human coronary arteries after angioplasty: safety results from phase I Kuopio angioplasty gene transfer trial (KAT trial) [abstract]. Circulation. 1998;98(suppl 17):l-320.
16. Mann MJ. Whittemore AD, Donaldson MC, et al. The PREVENT trial of vein graft genetic engineering: preliminary molecular and clinical findings [abstract]. Circulation. 1998;98(suppl 17):l-319.